In radiofrequency ablation (RFA), heat is projected into a tumor by a high-frequency, alternating current that flows from electrodes. The cells killed by RFA are gradually replaced by fibrosis and scar tissue. RFA can be performed percutaneously, laparoscopically, or as an open procedure.
Osteolytic Bone Pain
RFA may be considered medically necessary to palliate pain in individuals with osteolytic bone metastases who have failed or are poor candidates for standard treatments such as radiation or opioids.
RFA as initial treatment for painful bony metastases is considered experimental/investigational, and therefore, non- covered. The evidence is insufficient to determine the impact of the technology on health outcomes.
Osteoid Osteomas
RFA may be considered medically necessary to treat osteoid osteomas that cannot be managed successfully with medical treatment.
RFA for osteoid osteomas that can be managed with medical treatment is considered experimental/investigational, and therefore, non-covered. The evidence is insufficient to determine the impact of the technology on health outcomes.
20982 |
Isolated Peripheral Non-Small Cell Lung Cancer
RFA may be considered medically necessary to treat an isolated peripheral non-small-cell lung cancer lesion that is no more than three (3) cm in size when ALL the following criteria are met:
RFA for any other isolated peripheral non-small cell lung cancer is considered experimental/investigational, and is therefore, non-covered due to the evidence is insufficient to determine the impact of the technology on health outcomes.
Malignant Non-Pulmonary Tumor(s) Metastatic to the Lung
RFA may be considered medically necessary to treat malignant nonpulmonary tumor(s) metastatic to the lung that are no more than three (3) cm in size when the following criteria are met:
RFA for any other malignant non-pulmonary tumors metastatic to the lung is considered experimental/investigational, and is therefore, non-covered due to the evidence is insufficient to determine the impact of the technology on health outcomes.
32998 |
RFA is considered experimental/investigational and therefore non-covered as a technique for ablation of:
The evidence is insufficient to determine the impact of the technology on health outcomes.
20982 | 32998 |
Diagnosis Codes for 20982 and 32998
C34.00 | C34.01 | C34.02 | C34.10 | C34.11 | C34.12 | C34.2 |
C34.30 | C34.31 | C34.32 | C34.80 | C34.81 | C34.82 | C34.90 |
C34.91 | C34.92 | C40.00 | C40.01 | C40.02 | C40.10 | C40.11 |
C40.12 | C40.20 | C40.21 | C40.22 | C40.30 | C40.31 | C40.32 |
C79.00 | C79.01 | C79.02 | C79.51 | C79.52 | D16.00 | D16.01 |
D16.02 | D16.10 | D16.11 | D16.12 | D16.20 | D16.21 | D16.22 |
D16.30 | D16.31 | D16.32 | D16.4 | D16.5 | D16.6 | D16.7 |
D16.8 | D16.9 |
NA